SecBot SecBot
PRESS-RELEASE ·Filed Apr 27, 2026

FULC

Fulcrum Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The EPS beat vs consensus is modest and the company remains pre-revenue. The key catalyst is the upcoming FDA meeting and potential registration-enabling trial initiation in H2 2026. Monitor for FDA meeting minutes and trial design update expected in Q2 2026.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.72
T+0 close · Apr 27, 2026 · via day close
Latest settled
−52.07%
T+60 · $3.70
Vs SPY
−56.85%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $7.72entry
  2. T+1 · 7mo ago −3.63%α −3.14% · $7.44
  3. T+5 · 7mo ago −9.07%α −9.47% · $7.02
  4. T+20 · 6mo ago −12.44%α −17.39% · $6.76
  5. T+60 · 4mo ago −52.07%α −56.85% · $3.70
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fulcrum Therapeutics reported Q1 2026 net loss of $18.9M ($0.25 per share), slightly narrower than the consensus estimate of a $0.30 loss. The company highlighted positive clinical data for pociredir in sickle cell disease, plans to initiate a registration-enabling trial in H2 2026, and ended the quarter with $333.3M in cash, providing runway into 2029. CFO Alan Musso announced retirement later this year.

Key Financial Metrics

EPS
−$0.25
est −$0.30 · +16.7%
Revenue
$0.00
est $0.00
Rating
beat

Key Facts

  • Q1 2026 net loss of $18.9M ($0.25 per share) vs consensus estimate of $0.30 loss per share
  • Cash, cash equivalents and marketable securities of $333.3M as of March 31, 2026, down from $352.3M at year-end 2025
  • Positive clinical data from Phase 1b PIONEER trial of pociredir in sickle cell disease presented in Q1 2026
  • Plans to initiate a potential registration-enabling trial for pociredir in H2 2026 pending FDA feedback
  • CFO Alan Musso plans to retire later this year; search for successor initiated
  • Cash runway guidance extended into 2029

Financial Impact

Net loss of $18.9M, slightly better than consensus; cash burn of $19.0M in Q1; no revenue reported

net losscash positionoperating expenses

Risk Factors

  • Clinical-stage biotech with no approved products or revenue; depends on successful clinical development and regulatory approval of pociredir
  • CFO retirement introduces leadership transition risk
  • Cash burn rate may require additional financing before reaching profitability

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3281455

Track record

23 reports on FULC

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  4. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  5. Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  6. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  7. Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
  8. Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
  9. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
  10. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026